Abstract
Bladder cancer is one of the most common urogenital malignant with a rising incidence rate all over the world. Non-muscle invasive bladder cancer (NMIBC) has the characteristics of high recurrence rate and easy progression after receiving transurethral tumor resection combined with intravesical chemotherapy. The intrinsic or/and acquired drug resistance is mainly causing this poor outcome. The continuing advances in metabolomics and single-cell mass spectrometry have been considered as the key to promoting clinical precision medicine. Urinary exfoliated tumor cells (UETCs) carry the first-hand biological information on the genesis and progression of primary bladder cancer. Therefore, we hypothesized that the establishment of a drug resistance monitoring system for bladder cancer with intravesical chemotherapy based on UETCs single-cell metabolomics technology has a broad application prospect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
